Format

Send to

Choose Destination
Ind Psychiatry J. 2018 Jan-Jun;27(1):154-157. doi: 10.4103/ipj.ipj_20_16.

Flibanserin: A controversial drug for female hypoactive sexual desire disorder.

Author information

1
Department of Obstetrics and Gynecology, IPGME and R and SSKM Hospital, Kolkata, West Bengal, India.
2
Department of Cardiology, IPGME and R and SSKM Hospital, Kolkata, West Bengal, India.

Abstract

Sexual functioning is an integral part of human life. Female sexual dysfunction (FSD) adversely affects quality of life and general well-being. The Food and Drug Administration recently approved flibanserin, for treatment of female hypoactive sexual desire disorder (HSDD), regarded as the most common FSD, amid great controversy. A novel multifunctional serotonin agonist and antagonist, flibanserin, has been shown to be efficacious in treating HSDD but with a rather tenacious side effect profile. We review this interesting drug in its entirety. Data for the article were collected by reviewing articles on PubMed, the drug (Addyi) website, and related websites on the internet.

KEYWORDS:

Addyi; female hypoactive sexual desire disorder; flibanserin

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center